E-Mail 'Clinical Notes: Rat Data Suggest Eye Risk for CF Drug' To A Friend

Email a copy of 'Clinical Notes: Rat Data Suggest Eye Risk for CF Drug' to a friend

* Required Field






Separate multiple entries with a comma. Maximum 5 entries.



Separate multiple entries with a comma. Maximum 5 entries.


E-Mail Image Verification

Loading ... Loading ...

Clinical Notes: Rat Data Suggest Eye Risk for CF Drug

(MedPage Today) — Cataracts developed in young rats treated with the cystic fibrosis drug ivacaftor (Kalydeco), prompting the FDA to order a label change. Also this week: a fatal viral infection stalks Yosemite Park.

Clinical Notes: Rat Data Suggest Eye Risk for CF Drug

(MedPage Today) — Cataracts developed in young rats treated with the cystic fibrosis drug ivacaftor (Kalydeco), prompting the FDA to order a label change. Also this week: a fatal viral infection stalks Yosemite Park.

Clinical Notes: Rat Data Suggest Eye Risk for CF Drug

(MedPage Today) — Cataracts developed in young rats treated with the cystic fibrosis drug ivacaftor (Kalydeco), prompting the FDA to order a label change. Also this week: a fatal viral infection stalks Yosemite Park.

Clinical Notes: Rat Data Suggest Eye Risk for CF Drug

(MedPage Today) — Cataracts developed in young rats treated with the cystic fibrosis drug ivacaftor (Kalydeco), prompting the FDA to order a label change. Also this week: a fatal viral infection stalks Yosemite Park.